Oncternal Therapeutics Inc (ONCT) - Net Assets

Latest as of September 2024: $9.15 Million USD

Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has net assets worth $9.15 Million USD as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.60 Million) and total liabilities ($6.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Oncternal Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $9.15 Million
% of Total Assets 58.64%
Annual Growth Rate 35.36%
5-Year Change 109.98%
10-Year Change 68.56%
Growth Volatility 26798.44

Oncternal Therapeutics Inc - Net Assets Trend (1999–2023)

This chart illustrates how Oncternal Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Oncternal Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Oncternal Therapeutics Inc (1999–2023)

The table below shows the annual net assets of Oncternal Therapeutics Inc from 1999 to 2023. For live valuation and market cap data, see ONCT company net worth.

Year Net Assets Change
2023-12-31 $30.05 Million -50.71%
2022-12-31 $60.97 Million -30.81%
2021-12-31 $88.12 Million -21.98%
2020-12-31 $112.95 Million +689.20%
2019-12-31 $14.31 Million -45.19%
2018-12-31 $26.11 Million -31.76%
2017-12-31 $38.26 Million +92.35%
2016-12-31 $19.89 Million +969.98%
2015-12-31 $1.86 Million -89.57%
2014-12-31 $17.83 Million +66.88%
2013-12-31 $10.68 Million -77.60%
2012-12-31 $47.70 Million -33.63%
2011-12-31 $71.87 Million +38.95%
2010-12-31 $51.73 Million +691.17%
2009-12-31 $-8.75 Million -127.33%
2008-12-31 $32.02 Million -59.43%
2007-12-31 $78.92 Million -18.68%
2006-12-31 $97.05 Million +31.90%
2005-12-31 $73.58 Million +15.13%
2004-12-31 $63.91 Million +142.54%
2003-12-31 $-150.23 Million -171.63%
2002-12-31 $-55.31 Million -62.31%
2001-12-31 $-34.08 Million -35.41%
2000-12-31 $-25.16 Million -119933.33%
1999-12-31 $21.00K --

Equity Component Analysis

This analysis shows how different components contribute to Oncternal Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 19683000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Common Stock $3.00K 0.01%
Other Comprehensive Income $3.00K 0.01%
Other Components $227.82 Million 758.10%
Total Equity $30.05 Million 100.00%

Oncternal Therapeutics Inc Competitors by Market Cap

The table below lists competitors of Oncternal Therapeutics Inc ranked by their market capitalization.

Company Market Cap
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
 $1.56 Million
Foxtons Group Plc
LSE:FOXT
 $1.57 Million
BioSenic S.A.
BR:BIOS
 $1.57 Million
Trufin PLC
LSE:TRU
 $1.57 Million
Golden Cross Resources Ltd
AU:GCR
 $1.55 Million
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
 $1.55 Million
Hynion AS
OL:HYN
 $1.55 Million
Uniinfo Telecom Services Limited
NSE:UNIINFO
 $1.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Oncternal Therapeutics Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from -158,300,000 to 30,052,000, a change of 188,352,000.
  • Net loss of 39,479,000 reduced equity.
  • Share repurchases of 156,000 reduced equity.
  • New share issuances of 3,238,000 increased equity.
  • Other comprehensive income decreased equity by 6,000.
  • Other factors increased equity by 224,755,000.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income $-39.48 Million -131.37%
Share Repurchases $156.00K -0.52%
Share Issuances $3.24 Million +10.77%
Other Comprehensive Income $-6.00K -0.02%
Other Changes $224.75 Million +747.89%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Oncternal Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.05x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 2.77x to 0.05x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 $0.19 $0.53 x
2000-12-31 $-227.74 $0.53 x
2001-12-31 $-307.86 $0.53 x
2002-12-31 $-500.53 $0.53 x
2003-12-31 $-1359.54 $0.53 x
2004-12-31 $185.92 $0.53 x
2005-12-31 $198.23 $0.53 x
2006-12-31 $218.09 $0.53 x
2007-12-31 $158.10 $0.53 x
2008-12-31 $61.74 $0.53 x
2009-12-31 $-16.82 $0.53 x
2010-12-31 $93.14 $0.53 x
2011-12-31 $87.71 $0.53 x
2012-12-31 $53.16 $0.53 x
2013-12-31 $11.86 $0.53 x
2014-12-31 $15.26 $0.53 x
2015-12-31 $0.88 $0.53 x
2016-12-31 $9.56 $0.53 x
2017-12-31 $15.36 $0.53 x
2018-12-31 $7.83 $0.53 x
2019-12-31 $27.71 $0.53 x
2020-12-31 $-81.55 $0.53 x
2021-12-31 $-46.28 $0.53 x
2022-12-31 $-60.20 $0.53 x
2023-12-31 $10.22 $0.53 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Oncternal Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -131.37%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -5029.17%
  • • Asset Turnover: 0.02x
  • • Equity Multiplier: 1.22x
  • Recent ROE (-131.37%) is above the historical average (-246.36%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 -3571.43% 0.00% 0.00x 79.90x $-752.10K
2000 0.00% 0.00% 0.00x 0.00x $-1.30 Million
2001 0.00% 0.00% 0.00x 0.00x $-4.66 Million
2002 0.00% 0.00% 0.00x 0.00x $-6.34 Million
2003 0.00% 0.00% 0.00x 0.00x $829.10K
2004 -34.97% -1197.00% 0.03x 1.14x $-28.74 Million
2005 -50.07% -974.06% 0.05x 1.13x $-44.20 Million
2006 -36.59% -473.15% 0.06x 1.33x $-45.21 Million
2007 -51.14% -566.36% 0.04x 2.02x $-48.25 Million
2008 -161.72% -382.76% 0.13x 3.38x $-54.98 Million
2009 0.00% -314.03% 0.26x 0.00x $-45.38 Million
2010 29.57% 25.23% 0.94x 1.24x $10.12 Million
2011 -46.32% -225.89% 0.19x 1.09x $-40.48 Million
2012 -56.76% 0.00% 0.00x 1.21x $-31.85 Million
2013 -394.15% 0.00% 0.00x 1.46x $-43.18 Million
2014 -221.05% 0.00% 0.00x 2.84x $-41.19 Million
2015 -1006.08% 0.00% 0.00x 17.23x $-18.89 Million
2016 -89.11% 0.00% -0.10x 1.23x $-19.71 Million
2017 -79.56% -1818.34% 0.04x 1.21x $-34.27 Million
2018 -147.13% -1523.92% 0.08x 1.20x $-41.03 Million
2019 -111.18% -656.16% 0.11x 1.52x $-17.34 Million
2020 0.00% -509.90% 0.03x 0.00x $-8.93 Million
2021 0.00% -725.38% 0.05x 0.00x $-19.89 Million
2022 0.00% -2912.28% 0.02x 0.00x $-27.56 Million
2023 -131.37% -5029.17% 0.02x 1.22x $-42.48 Million

Industry Comparison

This section compares Oncternal Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $44,828,400
  • Average return on equity (ROE) among peers: -124.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Oncternal Therapeutics Inc (ONCT) $9.15 Million -3571.43% 0.71x $1.56 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $118.88 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $1.07 Billion
Abeona Therapeutics Inc (ABEO) $3.60 Million -91.89% 0.28x $292.09 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $171.87 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $448.19K
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $345.85 Million
Arbutus Biopharma Corp (ABUS) $88.00 Million -44.09% 0.34x $840.56 Million
ABVC Biopharma Inc (ABVC) $80.00K -31.70% 0.38x $26.41 Million
Abivax SA American Depositary Shares (ABVX) $40.58 Million -434.26% 4.06x $9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD) $23.36 Million -97.44% 0.37x $3.74 Billion

About Oncternal Therapeutics Inc

NASDAQ:ONCT USA Biotechnology
Market Cap
$1.56 Million
Market Cap Rank
#29905 Global
#5834 in USA
Share Price
$0.53
Change (1 day)
+0.00%
52-Week Range
$0.53 - $0.53
All Time High
$3533.60
Categories
Companies in USA Biotechnology
About

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more